远大医药(00512)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00512 远大医药

未开盘 12-23 16:08:09

8.300

+0.000

0.00%

最高8.360	最低8.210	成交量173.90万
今开8.330	昨收8.300	日振幅1.81%
总市值294.61亿	流通市值294.61亿	总股本35.50亿
成交额1,440万	换手率0.05%	流通股本35.50亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00512","market":"HK","secType":"STK","nameCN":"远大医药","latestPrice":8.3,"timestamp":1766477289002,"preClose":8.3,"halted":0,"volume":1739000,"delay":0,"floatShares":3549571148,"shares":3549571148,"eps":0.704885,"marketStatus":"未开盘","change":0,"latestTime":"12-23 16:08:09","open":8.33,"high":8.36,"low":8.21,"amount":14397159,"amplitude":0.018072,"askPrice":8.3,"askSize":35000,"bidPrice":8.29,"bidSize":6500,"shortable":3,"etf":0,"ttmEps":0.594325,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766539800000},"marketStatusCode":0,"adr":0,"listingDate":819302400000,"exchange":"SEHK","adjPreClose":8.3,"dividendRate":0.031325,"openAndCloseTimeList":[[1766453400000,1766462400000],[1766466000000,1766476800000]],"volumeRatio":0.2794278500294748,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00512","defaultTab":"news","newsList":[{"id":"2593474493","title":"远大医药(00512)引进全球首款用于治疗严重过敏反应的肾上腺素鼻喷雾剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2593474493","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593474493?lang=zh_cn&edition=full","pubTime":"2025-12-23 17:07","pubTimestamp":1766480850,"startTime":"0","endTime":"0","summary":"集团将获得全球首款用于紧急治疗成人和 30kg 及以上儿童患者以及 15-30kg 儿童患者I 型过敏反应的肾上腺素鼻喷雾剂 Neffy 在中国大陆合作渠道内的独家商业化权益以及在中国香港特别行政区的非独家商业化权益。此次，集团引进的全球创新肾上腺素鼻喷雾剂优敏速是 35 年来 FDA 首次批准的用于 I 型过敏反应的非注射治疗产品，有望提高肾上腺素治疗产品对中国严重过敏反应患者的可及性，并填补严重过敏反应急救药物在院外场景使用的空白。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384928.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00512","BK1191"],"gpt_icon":0},{"id":"2593208452","title":"每日卖空追踪 | 远大医药 12月22日卖空量成交17.2万股，卖空比例为4.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593208452","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593208452?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:30","pubTimestamp":1766392213,"startTime":"0","endTime":"0","summary":"远大医药北京时间12月22日，涨1.34%，卖空量成交17.2万股，较上一交易日减少77.29%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222163229a46992bf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222163229a46992bf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00512","BK1191"],"gpt_icon":0},{"id":"2593943679","title":"远大医药12月22日获主力加仓94.0万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2593943679","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593943679?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:16","pubTimestamp":1766391366,"startTime":"0","endTime":"0","summary":"12月22日, 远大医药股价涨1.34%，报收8.30元，成交金额3162.4万元，换手率0.11%，振幅1.34%，量比0.58。远大医药今日主力资金净流入94.0万元，上一交易日主力净流入573.4万元。该股近5个交易日上涨1.22%，主力资金累计净流出1085.7万元；近20日主力资金累计净流入373.6万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222162426a6c08e7d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222162426a6c08e7d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00512","BK1191"],"gpt_icon":0},{"id":"2593109015","title":"脑机接口医疗器械工作推进会召开；官方成立南极磷虾油事件调查组 | 健讯Daily","url":"https://stock-news.laohu8.com/highlight/detail?id=2593109015","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593109015?lang=zh_cn&edition=full","pubTime":"2025-12-22 07:42","pubTimestamp":1766360520,"startTime":"0","endTime":"0","summary":"国家药监局在北京召开脑机接口医疗器械工作推进会12月19日消息，国家药监局12月18日在北京召开脑机接口医疗器械工作推进会。下一步将根据调查结果依法依规进行严肃查处，坚决保护消费者合法权益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222074642a467b9a4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222074642a467b9a4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09996","BK1100","09997","00512","BK1222","BK1583","BK1574","BK1191"],"gpt_icon":0},{"id":"2593176432","title":"智通港股早知道 | 中国神华(01088)实施千亿资产重组 COMEX白银期货刷新历史纪录高位","url":"https://stock-news.laohu8.com/highlight/detail?id=2593176432","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593176432?lang=zh_cn&edition=full","pubTime":"2025-12-22 07:10","pubTimestamp":1766358602,"startTime":"0","endTime":"0","summary":"中国神华实施千亿资产重组智通财经APP讯，中国神华最新发布重大资产重组报告，宣布拟以发行股份及支付现金方式收购控股股东国家能源集团旗下12家核心企业股权，交易总对价达1335.98亿元，配套募集资金同步推进。COMEX白银期货收涨3.34%，报67.395美元/盎司，刷新历史纪录高位。此外，集团用于治疗前列腺癌的 RDC 产品 TLX591 已在中国获批加入国际多中心 III 期临床研究，未来，两款产品组合蓄势待发，有望为中国前列腺癌患者带来更为精准、高效的诊疗方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384147.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","601088","LU0173614495.USD","SG9999002950.SGD","SGXZ90724238.SGD","BK0187","06198","BK1505","BK0028","SG9999003461.SGD","BK1161","BK1173","BK1538","SG9999001093.SGD","SG9999001069.SGD","BK1567","00107","01088","BK0266","BK1185","BK1178","BK0179","BK0196","BK1225","BK1574","BK0015","01167","BK0006","01053","SG9999001051.SGD","BK1594","QImain","00512","BK0012","BK0010","SImain","SG9999006597.SGD","LU0287142896.SGD","HGmain","BK1568","BK1191"],"gpt_icon":0},{"id":"2593593124","title":"远大医药TLX591-CDx临床研究达主要临床终点，PPV达94.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593593124","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593593124?lang=zh_cn&edition=full","pubTime":"2025-12-21 19:07","pubTimestamp":1766315232,"startTime":"0","endTime":"0","summary":"12月21日，远大医药（00512）发布公告，本集团的创新放射性核素偶联药物TLX591-CDx在中国进行的III期临床研究成功达到主要临床终点，显示出积极的顶线结果。该研究的阳性预测值（PPV）达94.8%，其中针对复发在前列腺床区和转移到盆腔外的肿瘤，PPV为100.0%。此外，超过67.2%的患者在检测后其治疗方案发生了调整，表明该产品对临床决策具有重要影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512213597610455.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","00512"],"gpt_icon":0},{"id":"2593212811","title":"核药进展如潮涌！远大医药(00512)创新RDC药物TLX591-CDx国内III期达到主要临床终点，诊疗一体化布局蓄势待发","url":"https://stock-news.laohu8.com/highlight/detail?id=2593212811","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593212811?lang=zh_cn&edition=full","pubTime":"2025-12-21 18:14","pubTimestamp":1766312060,"startTime":"0","endTime":"0","summary":"目前，远大医药已有六款创新RDC获批开展注册性临床研究，其中四款已进入III期临床阶段，公司已进入创新核药产品的收获期。尤为值得一提的是，公司自主研发的全球创新FAP靶点小分子RDC药物GPN01530近期获FDA批准在美国开展诊断实体瘤的I/II期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384114.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00512","RDC","BK1191","BK4134","III"],"gpt_icon":0},{"id":"2593512143","title":"远大医药(00512)用于诊断前列腺癌的创新在研放射性核素偶联药物TLX591-CDx中国 III 期临床研究成功达到主要临床终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2593512143","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593512143?lang=zh_cn&edition=full","pubTime":"2025-12-21 18:10","pubTimestamp":1766311834,"startTime":"0","endTime":"0","summary":"智通财经APP讯，远大医药 公布，集团用于诊断前列腺癌的创新在研放射性核素偶联药物 TLX591-CDx 在中国进行的 III 期临床试验，近日取得了积极的顶线结果，并成功达到了主要临床终点。这表明 TLX591-CDx 的 PET 成像检测对临床决策具有重要影响，可优化疑似生化复发的前列腺癌患者的临床治疗策略。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384112.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","BK1191","00512","BK4134"],"gpt_icon":0},{"id":"2592663761","title":"每日卖空追踪 | 远大医药 12月19日卖空量成交31.4万股，卖空比例为4.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592663761","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592663761?lang=zh_cn&edition=full","pubTime":"2025-12-19 16:30","pubTimestamp":1766133013,"startTime":"0","endTime":"0","summary":"远大医药北京时间12月19日，涨2.63%，卖空量成交31.4万股，较上一交易日减少31.96%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219163121a6b6412e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219163121a6b6412e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","00512"],"gpt_icon":0},{"id":"2592324166","title":"远大医药12月19日主力净流入573.4万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2592324166","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592324166?lang=zh_cn&edition=full","pubTime":"2025-12-19 16:16","pubTimestamp":1766132164,"startTime":"0","endTime":"0","summary":"12月19日, 远大医药股价涨2.63%，报收8.19元，成交金额5773.5万元，换手率0.20%，振幅2.88%，量比1.04。远大医药今日主力资金净流入573.4万元，上一交易日主力净流出316.6万元。该股近5个交易日下跌0.98%，主力资金累计净流出1492.8万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流入511.8万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219162330a45f27c4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219162330a45f27c4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00512","BK1191"],"gpt_icon":0},{"id":"2592313331","title":"Go Global战略再突破 远大医药(00512)自研创新FAP靶点核药美国临床获批 撬动超千亿市场空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2592313331","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592313331?lang=zh_cn&edition=full","pubTime":"2025-12-19 08:27","pubTimestamp":1766104073,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，近日，中国医药创新领域迎来一项具有标杆意义的进展——远大医药自主研发的全球创新放射性核素偶联药物GPN01530正式获得FDA批准在美国开展用于诊断实体瘤的I/II期临床研究。公告显示，GPN01530优化了FAP配体的结构，提高了其在肿瘤组织中的摄取，同时降低其在正常组织中的摄取。近年来，远大医药核药产品在全球大放光彩，屡屡刷新海外临床进展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383443.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Go Global战略再突破 远大医药(00512)自研创新FAP靶点核药美国临床获批 撬动超千亿市场空间","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00512","BK1191"],"gpt_icon":0},{"id":"2592588111","title":"每日卖空追踪 | 远大医药 12月18日卖空量成交15.85万股，卖空比例为4.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592588111","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592588111?lang=zh_cn&edition=full","pubTime":"2025-12-18 16:30","pubTimestamp":1766046612,"startTime":"0","endTime":"0","summary":"远大医药北京时间12月18日，涨0.13%，卖空量成交15.85万股，较上一交易日减少86.86%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218163118a45a9ea3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218163118a45a9ea3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00512","BK1191"],"gpt_icon":0},{"id":"2592996689","title":"远大医药(00512)：自主研发的重磅全球创新放射性核素偶联药物 GPN01530 在美国获批开展临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2592996689","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592996689?lang=zh_cn&edition=full","pubTime":"2025-12-17 18:06","pubTimestamp":1765966009,"startTime":"0","endTime":"0","summary":"智通财经APP讯，远大医药 发布公告，集团自主研发的全球创新放射性核素偶联药物 GPN01530 近日获得美国食品药品监督管理局正式批准开展用于诊断实体瘤的 I/II 期临床研究，这标志着集团在核药抗肿瘤诊疗领域的全球化布局上又迈出坚实一步。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1382654.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00512","BK1161","BK1583","BK1191","01530","BK1593","HK0000165453.HKD"],"gpt_icon":0},{"id":"2592969955","title":"【券商聚焦】国元证券维持远大医药(0512.HK)“买入”评级 指核药管线推动业绩增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2592969955","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592969955?lang=zh_cn&edition=full","pubTime":"2025-12-16 09:37","pubTimestamp":1765849022,"startTime":"0","endTime":"0","summary":"金吾财讯|国元证券发布研报指，远大医药创新核药产品逐步上市将推动业绩持续增长，维持“买入”评级，目标价11.88港元，较现价有45.23%上涨空间。报告显示，公司25年中期实现总营业收入61.1亿港元，人民币口径同比增长2.0%。钇[90Y]微球注射液获批不可切除HCC适应症。该产品成为全球首个获FDA批准用于治疗不可切除HCC和结直肠癌肝转移双重适应症的SIRT产品。主要风险包括新产品研发进度低于预期及商业化进展不达预期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216095359a6a74c86&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216095359a6a74c86&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00512"],"gpt_icon":0},{"id":"2591983377","title":"中核集团攻克富集靶材辐照制备碘-131全链条技术 核药市场呈现高速增长（附概念股）","url":"https://stock-news.laohu8.com/highlight/detail?id=2591983377","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591983377?lang=zh_cn&edition=full","pubTime":"2025-12-16 08:41","pubTimestamp":1765845673,"startTime":"0","endTime":"0","summary":"平台充分发挥集团内部协同创新优势，整合中国原子能所属核理化院、核动力院、中核高通、中核二七二铀业，攻克富集 TeO 靶材辐照制备碘-131全产业链技术，形成了从碘-131前置核素制备、反应堆辐照到核药研发的完整环境友好型自主产业链。中国同位素与辐射行业协会秘书长郭丽莉介绍，截至2024年，国家药监局批准上市的放射治疗设备超90款，其中国产品牌占比超七成，彻底改变了此前依赖进口设备的局面。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216090508a6a717ba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216090508a6a717ba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00512","01763","BK1161","BK1222","BK1191","01244"],"gpt_icon":0},{"id":"2591470614","title":"国元国际：维持远大医药(00512)“买入”评级 目标价格为11.88港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2591470614","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591470614?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:52","pubTimestamp":1765788739,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国元国际发布研报称，远大医药创新产品逐步上市，推动业绩持续增长。国元国际主要观点如下：创新药推动收入增长25年中期实现总营业收入61.1亿港元，人民币口径同比增长2.0%；正常化溢利10.2亿港元，人民币口径同比下降5.0%。主要业务板块中，制药科技产品贡献最大，收入为港币38.45亿元，人民币口径同比上涨2.9%。盈利预测预计未来公司业绩将持续增长，预计2024-2026年收入分别为123.5亿和133.9亿、147.9亿港币；EPS分别为0.59、0.66、0.77港币。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381550.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["00512"],"gpt_icon":0},{"id":"2591402266","title":"远大医药12月15日遭主力抛售313.0万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2591402266","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591402266?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:15","pubTimestamp":1765786516,"startTime":"0","endTime":"0","summary":"12月15日, 远大医药股价跌0.12%，报收8.17元，成交金额4648.4万元，换手率0.16%，振幅3.79%，量比0.78。远大医药今日主力资金净流出313.0万元，上一交易日主力净流出186.5万元。该股近5个交易日上涨0.74%，主力资金累计净流入411.1万元；近20日主力资金累计净流入2127.0万元，其中净流入天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215161602a44d2abf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215161602a44d2abf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00512","BK1191"],"gpt_icon":0},{"id":"2590512501","title":"远大医药12月11日主力净流入407.8万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2590512501","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590512501?lang=zh_cn&edition=full","pubTime":"2025-12-11 16:16","pubTimestamp":1765440960,"startTime":"0","endTime":"0","summary":"12月11日, 远大医药股价涨1.11%，报收8.20元，成交金额7666.7万元，换手率0.26%，振幅3.95%，量比1.85。远大医药今日主力资金净流入407.8万元，上一交易日主力净流出49.0万元。该股近5个交易日下跌0.24%，主力资金累计净流入558.1万元；近20日主力资金累计净流入2819.8万元，其中净流入天数为15日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211162309953756f1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211162309953756f1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","00512"],"gpt_icon":0},{"id":"2590565006","title":"港股异动 | 远大医药(00512)盘中涨超3% 中药创新药GPN01360国内II期临床达到终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2590565006","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590565006?lang=zh_cn&edition=full","pubTime":"2025-12-11 11:40","pubTimestamp":1765424423,"startTime":"0","endTime":"0","summary":"消息面上，远大医药近日公布，用于治疗抑郁症的中药创新药GPN01360在中国开展的Ⅱ期临床研究达到临床终点。远大医药表示，积极的临床研究数据为GPN01360后续的研发奠定了基础，并有望解决现有西药因副作用导致患者依从性差的难题，从而提高长期治疗的持续性和有效性，为提升抑郁症的临床治愈率带来新的方案。同时，GPN01360也将为中医药治疗抑郁症此类精神类疾病提供有力的循证医学证据，验证中成药的独特优势与科学价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380261.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","00512","BK1191","06978","159992","BK1161"],"gpt_icon":0},{"id":"2590699512","title":"又一突破，远大医药重磅抗抑郁1.1类新药迎来新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2590699512","media":"北京药研汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590699512?lang=zh_cn&edition=full","pubTime":"2025-12-11 08:01","pubTimestamp":1765411280,"startTime":"0","endTime":"0","summary":"近日，2025年12月8日，远大医药发布公告，集团用于治疗抑郁症的中药创新药GPN01360在中国开展的II期临床研究成功达到临床终点。其中佐力药业的乌灵胶囊2022年销售额达10亿元，证明了国产抗抑郁中药的市场价值。希望远大医药的GPN01360后续临床试验及注册申报工作顺利推进，若成功获批上市，将为广大抑郁症患者提供新的治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211080930a4410908&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211080930a4410908&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00512","BK1191"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.chinagrandpharm.com","stockEarnings":[{"period":"1week","weight":0.0427},{"period":"1month","weight":0.0234},{"period":"3month","weight":-0.0235},{"period":"6month","weight":-0.0371},{"period":"1year","weight":0.8318},{"period":"ytd","weight":0.8087}],"compareEarnings":[{"period":"1week","weight":0.0213},{"period":"1month","weight":0.022},{"period":"3month","weight":-0.0281},{"period":"6month","weight":0.0596},{"period":"1year","weight":0.2963},{"period":"ytd","weight":0.2849}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"远大医药健康控股有限公司是一家主要从事制造及销售医药制剂及医疗器械的香港投资控股公司。该公司主要从事制造及销售医药制剂及医疗器械、生物技术产品及营养产品、精品原料药和其他产品。该公司的主要产品涵盖抗肿瘤、心血管急救制剂及高端心脑血管介入医疗器械、抗病毒抗感染、呼吸及五官科以及生物健康产品和精品原料药。","yearOnYearQuotes":[{"month":1,"riseRate":0.466667,"avgChangeRate":0.087032},{"month":2,"riseRate":0.7,"avgChangeRate":0.108479},{"month":3,"riseRate":0.4,"avgChangeRate":0.019078},{"month":4,"riseRate":0.633333,"avgChangeRate":0.018767},{"month":5,"riseRate":0.466667,"avgChangeRate":0.084333},{"month":6,"riseRate":0.366667,"avgChangeRate":-0.048262},{"month":7,"riseRate":0.366667,"avgChangeRate":-0.015905},{"month":8,"riseRate":0.4,"avgChangeRate":0.007133},{"month":9,"riseRate":0.466667,"avgChangeRate":-0.039275},{"month":10,"riseRate":0.5,"avgChangeRate":-0.014834},{"month":11,"riseRate":0.5,"avgChangeRate":0.085694},{"month":12,"riseRate":0.533333,"avgChangeRate":-0.005772}],"exchange":"SEHK","name":"远大医药","nameEN":"GRAND PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"远大医药(00512)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供远大医药(00512)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"远大医药,00512,远大医药股票,远大医药股票老虎,远大医药股票老虎国际,远大医药行情,远大医药股票行情,远大医药股价,远大医药股市,远大医药股票价格,远大医药股票交易,远大医药股票购买,远大医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"远大医药(00512)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供远大医药(00512)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}